PROCEPT BioRobotics Corporation (PRCT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
28/53
2.6 / 5 stars
All 53 Win/Lose results and 67 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LosePRCT / S&P -9.72% / 15.20% |
WinPRCT / S&P 22.69% / 15.00% |
LosePRCT / S&P 25.97% / 50.40% |
| 2026-Q11/3 |
LosePRCT / S&P -20.50% / -4.33% |
WinPRCT / S&P 29.26% / 11.30% |
LosePRCT / S&P 7.69% / 27.70% |
| 2025-Q41/3 |
LosePRCT / S&P -11.85% / 2.65% |
WinPRCT / S&P 37.22% / 9.00% |
LosePRCT / S&P -2.29% / 13.40% |
| 2025-Q31/3 |
LosePRCT / S&P -38.04% / 8.12% |
WinPRCT / S&P 50.07% / 4.61% |
LosePRCT / S&P -22.05% / 13.45% |
| 2025-Q21/3 |
LosePRCT / S&P -1.13% / 10.94% |
WinPRCT / S&P 55.71% / 4.83% |
LosePRCT / S&P -25.24% / 10.63% |
| 2025-Q11/3 |
LosePRCT / S&P -27.65% / -4.27% |
WinPRCT / S&P 59.36% / 4.98% |
LosePRCT / S&P -20.28% / 10.57% |
| 2024-Q41/3 |
LosePRCT / S&P 0.50% / 2.41% |
WinPRCT / S&P 64.84% / 5.25% |
LosePRCT / S&P -21.88% / 6.15% |
| 2024-Q32/3 |
WinPRCT / S&P 31.15% / 5.89% |
WinPRCT / S&P 71.71% / 5.89% |
LosePRCT / S&P -16.31% / 6.11% |
| 2024-Q22/3 |
WinPRCT / S&P 23.61% / 4.28% |
WinPRCT / S&P 73.74% / 5.38% |
LosePRCT / S&P -11.59% / 5.12% |
| 2024-Q12/3 |
WinPRCT / S&P 17.92% / 10.56% |
WinPRCT / S&P 83.44% / 5.71% |
LosePRCT / S&P -3.64% / 5.59% |
| 2023-Q43/3 |
WinPRCT / S&P 27.74% / 11.69% |
WinPRCT / S&P 81.55% / 6.81% |
WinPRCT / S&P 14.29% / 7.78% |
| 2023-Q31/3 |
LosePRCT / S&P -7.19% / -3.27% |
WinPRCT / S&P 89.63% / 7.52% |
LosePRCT / S&P -442.65% / -5.03% |
| 2023-Q23/3 |
WinPRCT / S&P 24.47% / 8.74% |
WinPRCT / S&P 104.52% / 9.50% |
WinPRCT / S&P 7666.67% / -8.57% |
| 2023-Q12/3 |
LosePRCT / S&P -31.63% / 7.50% |
WinPRCT / S&P 105.46% / 10.77% |
WinPRCT / S&P -0.00% / -15.69% |
| 2022-Q41/3 |
LosePRCT / S&P 0.19% / 7.56% |
WinPRCT / S&P 117.60% / 11.88% |
LosePRCT / S&P -56.05% / -17.99% |
| 2022-Q32/3 |
WinPRCT / S&P 26.83% / -4.88% |
WinPRCT / S&P 122.72% / 13.47% |
LosePRCT / S&P -107.08% / -1.41% |
| 2022-Q22/3 |
WinPRCT / S&P -6.57% / -16.10% |
WinPRCT / S&P 136.68% / 13.71% |
LosePRCT / S&P -99.73% / 11.04% |
| 2022-Q11/1 |
WinPRCT / S&P 39.90% / -4.60% |
No dataPRCT / S&P / 15.97% |
No dataPRCT / S&P / 42.23% |
| 2021-Q40/1 |
LosePRCT / S&P -34.44% / 11.03% |
No dataPRCT / S&P / 15.00% |
No dataPRCT / S&P / 96.40% |
| 2021-Q30/0 |
No dataPRCT / S&P / 0.58% |
No dataPRCT / S&P / 10.77% |
No dataPRCT / S&P / 69.42% |
| 2021-Q20/0 |
No dataPRCT / S&P / 8.55% |
No dataPRCT / S&P / 6.58% |
No dataPRCT / S&P / 51.81% |
| 2021-Q10/0 |
No dataPRCT / S&P / 6.17% |
No dataPRCT / S&P / -1.06% |
No dataPRCT / S&P / 7.39% |
| 2020-Q40/0 |
No dataPRCT / S&P / 12.15% |
No dataPRCT / S&P / -3.72% |
No dataPRCT / S&P / -33.42% |
| 2020-Q30/0 |
No dataPRCT / S&P / 8.93% |
No dataPRCT / S&P / -2.04% |
No dataPRCT / S&P / -27.10% |
| 2020-Q20/0 |
No dataPRCT / S&P / 20.54% |
No dataPRCT / S&P / -0.46% |
No dataPRCT / S&P / -27.11% |
| 2020-Q10/0 |
No dataPRCT / S&P / -19.60% |
No dataPRCT / S&P / 3.47% |
No dataPRCT / S&P / -14.75% |
| 2019-Q40/0 |
No dataPRCT / S&P / 9.07% |
No dataPRCT / S&P / 5.36% |
No dataPRCT / S&P / 2.99% |
| 2019-Q30/0 |
No dataPRCT / S&P / 1.70% |
No dataPRCT / S&P / 5.02% |
No dataPRCT / S&P / 0.21% |
| 2019-Q20/0 |
No dataPRCT / S&P / 4.30% |
No dataPRCT / S&P / 6.64% |
No dataPRCT / S&P / 8.65% |
| 2019-Q10/0 |
No dataPRCT / S&P / 13.65% |
No dataPRCT / S&P / 8.12% |
No dataPRCT / S&P / 14.29% |
| 2018-Q40/0 |
No dataPRCT / S&P / -13.52% |
No dataPRCT / S&P / 9.05% |
No dataPRCT / S&P / 18.23% |
| 2018-Q30/0 |
No dataPRCT / S&P / 7.71% |
No dataPRCT / S&P / 10.21% |
No dataPRCT / S&P / 19.06% |
| 2018-Q20/0 |
No dataPRCT / S&P / 3.43% |
No dataPRCT / S&P / 9.03% |
No dataPRCT / S&P / 14.46% |
| 2018-Q10/0 |
No dataPRCT / S&P / -0.76% |
No dataPRCT / S&P / 7.68% |
No dataPRCT / S&P / 12.46% |
| 2017-Q40/0 |
No dataPRCT / S&P / 6.64% |
No dataPRCT / S&P / 7.03% |
No dataPRCT / S&P / 13.82% |
| 2017-Q30/0 |
No dataPRCT / S&P / 4.48% |
No dataPRCT / S&P / 5.68% |
No dataPRCT / S&P / 17.57% |
| 2017-Q20/0 |
No dataPRCT / S&P / 3.09% |
No dataPRCT / S&P / 4.83% |
No dataPRCT / S&P / 17.74% |
| 2017-Q10/0 |
No dataPRCT / S&P / 6.07% |
No dataPRCT / S&P / 3.67% |
No dataPRCT / S&P / 13.32% |
| 2016-Q40/0 |
No dataPRCT / S&P / 3.82% |
No dataPRCT / S&P / 2.09% |
No dataPRCT / S&P / 7.05% |
| 2016-Q30/0 |
No dataPRCT / S&P / 3.85% |
No dataPRCT / S&P / 0.20% |
No dataPRCT / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -48.72% | 20.78% |
| Annualized return | -48.72% | 20.78% |
5Y · 2021-09-15 to 2026-08-27
| Metric | PRCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.88% | 83.14% |
| Annualized return | -13.25% | 12.86% |
10Y · 2021-09-15 to 2026-08-27
| Metric | PRCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.88% | 319.30% |
| Annualized return | -6.86% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |